drug
bosutinib
Marketedupdated 3mo agoby Alembic Pharmaceuticals Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4all catalysts(0)
nothing on the calendar yet
Trials studying bosutinib
- phase3Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs
- phase2iPSC-based Drug Repurposing for ALS Medicine (iDReAM) Study
- phase4Asciminib Roll-over Study
- phase3A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
- phase2Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
- phase2Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia
- phase3Study of Olverembatinib (HQP1351) in Patients With CP-CML
- phase1WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 26, 2026
37 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (40)
- Aug 28, 2034patentUS 11103497*PED
- Aug 28, 2034patentUS 11103497*PED
- Aug 28, 2034patentUS 11103497*PED
- Aug 28, 2034patentUS 11103497*PED
- Aug 28, 2034patentUS 11103497*PED
- Feb 28, 2034method-of-use (U-3217)US 11103497
- Feb 28, 2034method-of-use (U-3217)US 11103497
- Feb 28, 2034method-of-use (U-3217)US 11103497
- Feb 28, 2034method-of-use (U-3217)US 11103497
- Feb 28, 2034method-of-use (U-3217)US 11103497
- May 23, 2027patentUS 7767678*PED276d
- May 23, 2027patentUS 7767678*PED276d
- May 23, 2027patentUS 7767678*PED276d
- May 23, 2027patentUS 7767678*PED276d
- May 23, 2027patentUS 7767678*PED276d
- Nov 23, 2026compositionUS 776767895d
- Nov 23, 2026compositionUS 776767895d
- Nov 23, 2026compositionUS 776767895d
- Nov 23, 2026compositionUS 776767895d
- Nov 23, 2026compositionUS 776767895d
- Jun 11, 2026patentUS 7417148*PED
- Jun 11, 2026patentUS 7417148*PED
- Jun 11, 2026patentUS 7417148*PED
- Jun 11, 2026patentUS 7417148*PED
- Jun 11, 2026patentUS 7417148*PED
- Jun 11, 2026patentUS 7919625*PED
- Jun 11, 2026patentUS 7919625*PED
- Jun 11, 2026patentUS 7919625*PED
- Jun 11, 2026patentUS 7919625*PED
- Jun 11, 2026patentUS 7919625*PED
- Dec 11, 2025method-of-use (U-3708)US 7417148
- Dec 11, 2025method-of-use (U-3708)US 7417148
- Dec 11, 2025method-of-use (U-3707)US 7417148
- Dec 11, 2025method-of-use (U-3707)US 7417148
- Dec 11, 2025method-of-use (U-3708)US 7417148
- Dec 11, 2025formulationUS 7919625
- Dec 11, 2025formulationUS 7919625
- Dec 11, 2025formulationUS 7919625
- Dec 11, 2025formulationUS 7919625
- Dec 11, 2025formulationUS 7919625
FDA exclusivities (20)
- Mar 26, 2031PEDPediatric (6mo bonus)4.6y
- Mar 26, 2031PEDPediatric (6mo bonus)4.6y
- Mar 26, 2031PEDPediatric (6mo bonus)4.6y
- Mar 26, 2031PEDPediatric (6mo bonus)4.6y
- Mar 26, 2031PEDPediatric (6mo bonus)4.6y
- Sep 26, 2030ODE-444Orphan Drug (7y)4.1y
- Sep 26, 2030ODE-444Orphan Drug (7y)4.1y
- Sep 26, 2030ODE-444Orphan Drug (7y)4.1y
- Sep 26, 2030ODE-444Orphan Drug (7y)4.1y
- Sep 26, 2030ODE-444Orphan Drug (7y)4.1y
- Mar 26, 2027PEDPediatric (6mo bonus)218d
- Mar 26, 2027PEDPediatric (6mo bonus)218d
- Mar 26, 2027PEDPediatric (6mo bonus)218d
- Mar 26, 2027PEDPediatric (6mo bonus)218d
- Mar 26, 2027PEDPediatric (6mo bonus)218d
- Sep 26, 2026I-923Indication (3y)37d
- Sep 26, 2026NPNP37d
- Sep 26, 2026I-923Indication (3y)37d
- Sep 26, 2026I-923Indication (3y)37d
- Sep 26, 2026NPNP37d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 46m ago
Found something off?
comments(0)
5-min edit window · permanent after that